Fennec: FDA Accepts New Drug Application Resubmission for PEDMARK

  Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~

~ NDA Resubmission for PEDMARK for the Prevention of Cisplatin-Induced Ototoxicity for Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~

~ If Approved by the FDA, PEDMARK Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~

https://finance.yahoo.com/news/fennec-pharmaceuticals-announces-fda-acceptance-100000934.html